Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DNA-HIV-PT123 and AIDSVAX B/E in HIV-Uninfected Adults with or without Schistosoma Mansoni
NCT02376582Phase 1Completed
- Sponsor
- EuroVacc Foundation
- Start
- Sep 2014
- Primary completion
- Jan 2016
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DNA-HIV-PT123 and AIDSVAX B/E in human immunodeficiency virus infection (HIV) (2 arms), sponsored by EuroVacc Foundation. Primary endpoints: Proportion of volunteers with local and systemic reactogenicity events, Proportion of volunteers with adverse events and 2 more. Started Sep 2014; status: completed.
02
Drugs
DNA-HIV-PT123AIDSVAX B/E
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02376582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02376582.